Germline PALB2-mutated triple negative breast cancer treated with Olaparib in a kidney transplant patient
Olaparib, a poly(ADP-ribose) polymerase inhibitor, is a commonly used agent in the treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer carrying germline BRCA1/2 pathogenic variants. Phase II evidence has demonstrated antitumor activity in patients with partner and localizer of BRCA2...